CHICAGO (GenomeWeb) – Sophia Genetics said that it has received a CE-IVD mark for a molecular diagnostics test designed to improve detection of leukemia and other hematological diseases. The Swiss company called this the "world’s first capture-based myeloid clinical solution" to receive this designation from European regulators.

The test is a sequencing-based assay combined with data analytics to detect mutations that cause myeloid and lymphoid leukemia.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.